180 related articles for article (PubMed ID: 38035495)
1. A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis.
Dahal S; Allette YM; Naunton K; Harrison DM
Mult Scler Relat Disord; 2024 Jan; 81():105344. PubMed ID: 38035495
[TBL] [Abstract][Full Text] [Related]
2. Meningeal contrast enhancement in multiple sclerosis: Assessment of field strength, acquisition delay, and clinical relevance.
Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J
PLoS One; 2024; 19(5):e0300298. PubMed ID: 38809920
[TBL] [Abstract][Full Text] [Related]
3. Meningeal contrast enhancement in multiple sclerosis: assessment of field strength, acquisition delay, and clinical relevance.
Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J
medRxiv; 2024 Mar; ():. PubMed ID: 38496664
[TBL] [Abstract][Full Text] [Related]
4. No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
Ighani M; Jonas S; Izbudak I; Choi S; Lema-Dopico A; Hua J; O'Connor EE; Harrison DM
Mult Scler; 2020 Feb; 26(2):165-176. PubMed ID: 31573837
[TBL] [Abstract][Full Text] [Related]
5. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
Zurawski J; Tauhid S; Chu R; Khalid F; Healy BC; Weiner HL; Bakshi R
Mult Scler; 2020 Feb; 26(2):177-187. PubMed ID: 31714181
[TBL] [Abstract][Full Text] [Related]
6. Leptomeningeal Enhancement at 7T in Multiple Sclerosis: Frequency, Morphology, and Relationship to Cortical Volume.
Harrison DM; Wang KY; Fiol J; Naunton K; Royal W; Hua J; Izbudak I
J Neuroimaging; 2017 Sep; 27(5):461-468. PubMed ID: 28464368
[TBL] [Abstract][Full Text] [Related]
7. Leptomeningeal Enhancement on 3D-FLAIR MRI in Multiple Sclerosis: Systematic Observations in Clinical Practice.
Titelbaum DS; Engisch R; Schwartz ED; Napoli SQ; Sloane JA; Samaan S; Katz JD; Lathi ES
J Neuroimaging; 2020 Nov; 30(6):917-929. PubMed ID: 32830899
[TBL] [Abstract][Full Text] [Related]
8. Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.
Friedli C; Wagner F; Hammer HN; Kamber N; Wiest R; Diem L; Chan A; Salmen A; Hoepner R
Mult Scler; 2023 Jan; 29(1):63-73. PubMed ID: 36113094
[TBL] [Abstract][Full Text] [Related]
9. Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
Vercellino M; Costantini G; Cogoni M; Lequio L; Sciortino P; De Negri F; Marasciulo S; Valentini C; Bosa C; Garelli P; Rolando A; Calvo A; Morana G; Cavalla P
Mult Scler; 2023 Nov; 29(13):1526-1539. PubMed ID: 37740714
[TBL] [Abstract][Full Text] [Related]
10. Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
Mizell R; Chen H; Lambe J; Saidha S; Harrison DM
Mult Scler; 2022 Mar; 28(3):393-405. PubMed ID: 34125629
[TBL] [Abstract][Full Text] [Related]
11. Highly Sensitive 3-Tesla Real Inversion Recovery MRI Detects Leptomeningeal Contrast Enhancement in Chronic Active Multiple Sclerosis.
Okar SV; Dieckhaus H; Beck ES; Gaitán MI; Norato G; Pham DL; Absinta M; Cortese IC; Fletcher A; Jacobson S; Nair G; Reich DS
Invest Radiol; 2024 Mar; 59(3):243-251. PubMed ID: 37493285
[TBL] [Abstract][Full Text] [Related]
12. Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study.
Zivadinov R; Jakimovski D; Ramanathan M; Benedict RH; Bergsland N; Dwyer MG; Weinstock-Guttman B
Mult Scler Relat Disord; 2022 Nov; 67():104094. PubMed ID: 35964555
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Persistence of Meningeal Enhancement on Postcontrast 7T 3D-FLAIR MRI in Multiple Sclerosis.
Jonas SN; Izbudak I; Frazier AA; Harrison DM
AJNR Am J Neuroradiol; 2018 Oct; 39(10):1799-1805. PubMed ID: 30213813
[TBL] [Abstract][Full Text] [Related]
14. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials.
Krishnan AP; Song Z; Clayton D; Gaetano L; Jia X; de Crespigny A; Bengtsson T; Carano RAD
Radiology; 2022 Mar; 302(3):662-673. PubMed ID: 34904871
[TBL] [Abstract][Full Text] [Related]
15. [Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report].
Boyko OV; Khoroshylova II; Petrov SV; Lush NY; Guseva ME; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(8. Vyp. 2):116-120. PubMed ID: 30160679
[TBL] [Abstract][Full Text] [Related]
16. Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis.
Hildesheim FE; Ramasamy DP; Bergsland N; Jakimovski D; Dwyer MG; Hojnacki D; Lizarraga AA; Kolb C; Eckert S; Weinstock-Guttman B; Zivadinov R
Mult Scler Relat Disord; 2021 Jan; 47():102653. PubMed ID: 33333417
[TBL] [Abstract][Full Text] [Related]
17. Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation.
Marchi L; Mariottini A; Viti V; Bianchi A; Nozzoli C; Repice AM; Boncompagni R; Ginestroni A; Damato V; Barilaro A; Chiti S; Saccardi R; Fainardi E; Massacesi L
Front Neurol; 2024; 15():1373385. PubMed ID: 38899059
[TBL] [Abstract][Full Text] [Related]
18. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
19. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
[TBL] [Abstract][Full Text] [Related]
20. Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis.
Ineichen BV; Tsagkas C; Absinta M; Reich DS
Neuroimage Clin; 2022; 33():102939. PubMed ID: 35026625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
